| Not Yet Recruiting | Prospective Cohort Study of Pheochromocytoma/Paraganglioma NCT07516275 | Peking Union Medical College Hospital | — |
| Recruiting | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metast NCT04119024 | Anusha Kalbasi | Phase 1 |
| Not Yet Recruiting | Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors NCT07200245 | Central Hospital, Nancy, France | — |
| Not Yet Recruiting | Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma NCT06429397 | Sun Yat-sen University | Phase 2 |
| Recruiting | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal NCT06427798 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System NCT06233903 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | Phase 2 |
| Recruiting | Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis an NCT07195500 | Nanjing First Hospital, Nanjing Medical University | — |
| Recruiting | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for NCT06607692 | Fundación de investigación HM | Phase 1 / Phase 2 |
| Recruiting | Institutional Registry of Rare Diseases NCT06573723 | Hospital Italiano de Buenos Aires | — |
| Recruiting | Using the EHR to Advance Genomic Medicine Across a Diverse Health System NCT06377033 | University of Pennsylvania | N/A |
| Recruiting | Hereditary Pheochromocytoma Assessment of Tumour Immunologies NCT06444607 | Radboud University Medical Center | — |
| Recruiting | The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocyto NCT06440122 | King's College Hospital NHS Trust | — |
| Not Yet Recruiting | Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study NCT04788927 | Rigshospitalet, Denmark | — |
| Recruiting | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumo NCT05636618 | Perspective Therapeutics | Phase 1 / Phase 2 |
| Recruiting | "Receptor Radionuclide Therapy With 177Lu-DOTATOC NCT06045260 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Recruiting | Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy NCT06050057 | University Hospital Olomouc | — |
| Recruiting | In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma NCT05636540 | Heather Wachtel | EARLY_Phase 1 |
| Recruiting | 18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma NCT06813742 | First Affiliated Hospital of Zhejiang University | — |
| Unknown | A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL NCT05885386 | Peking Union Medical College Hospital | Phase 2 |
| Terminated | Metabolic Myopathy in Endocrinopathy NCT05456997 | Barts & The London NHS Trust | — |
| Recruiting | The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma NCT05702944 | Seoul National University Hospital | Phase 4 |
| Active Not Recruiting | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs NCT04711135 | Advanced Accelerator Applications | Phase 2 |
| Recruiting | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients NCT06523582 | Universidad Nacional Autonoma de Mexico | — |
| Unknown | Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma NCT05451134 | China National Center for Cardiovascular Diseases | — |
| Unknown | Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data NCT06229405 | Seoul National University Hospital | — |
| Unknown | A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL NCT05883085 | Peking Union Medical College Hospital | Phase 2 |
| Active Not Recruiting | Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death NCT05446779 | Helsinki University Central Hospital | — |
| Unknown | Genetic Factors and Pheochromocytomas in Neoplasia Type 2 NCT05158712 | Assistance Publique Hopitaux De Marseille | — |
| Recruiting | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor NCT05069220 | Peking Union Medical College Hospital | EARLY_Phase 1 |
| Recruiting | China Adrenal Disease Registry NCT04890444 | Shanghai Jiao Tong University School of Medicine | — |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Unknown | Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paragan NCT04573816 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CAB NCT04400474 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 |
| Withdrawn | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents NCT03923257 | Sue O'Dorisio | Phase 1 / Phase 2 |
| Completed | Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta- NCT04557072 | Jagiellonian University | — |
| Completed | Metanephrines in Obstructive Sleep Apnoea NCT05053685 | Changi General Hospital | — |
| Terminated | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Par NCT04187404 | Enterome | Phase 1 / Phase 2 |
| Terminated | Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROB NCT04605848 | University of Avignon | N/A |
| Withdrawn | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Prima NCT04276597 | Excel Diagnostics and Nuclear Oncology Center | Phase 2 |
| Completed | Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics NCT06669481 | Peking Union Medical College Hospital | — |
| Unknown | Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease NCT04891081 | University Medical Centre Ljubljana | — |
| Terminated | Cryoablation of Bone Metastases From Endocrine Tumors NCT03986593 | Instituto do Cancer do Estado de São Paulo | N/A |
| Completed | the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma NCT04320589 | National Cancer Institute, Egypt | Phase 2 |
| Active Not Recruiting | LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) NCT03946527 | Antonio Fojo | Phase 2 |
| Active Not Recruiting | 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma NCT03541720 | St. Jude Children's Research Hospital | EARLY_Phase 1 |
| Active Not Recruiting | Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma NCT03839498 | Columbia University | Phase 2 |
| Completed | Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma NCT05082311 | Sanjay Gandhi Postgraduate Institute of Medical Sciences | — |
| Completed | Prevention of Conversion in Posterior Retroperitoneal Adrenalectomy by Measuring Preoperative Anatomical Condi NCT04071561 | University of Basel | — |
| Enrolling By Invitation | A Prospective Cohort Study for Patients With Adrenal Diseases NCT03474237 | Seoul National University Hospital | — |
| Active Not Recruiting | DOTATOC PET/CT for Imaging NET Patients NCT03583528 | British Columbia Cancer Agency | — |
| Recruiting | Multicenter Pheochromocytoma and Paraganglioma Evaluation NCT03344016 | Felix Beuschlein | N/A |
| Recruiting | Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma NCT03206060 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Parag NCT05948137 | Asan Medical Center | — |
| Terminated | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With NCT03165721 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Surgeon-Anesthesiologist Collaboration NCT03158870 | Hospices Civils de Lyon | — |
| Completed | Preoperative Alpha Blockade for Pheochromocytoma NCT03176693 | University of California, Los Angeles | Phase 3 |
| Completed | Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for Pheochromocytoma NCT06062082 | Central Hospital, Nancy, France | — |
| Completed | Efficacy and Safety of Posterior Retroperitoneoscopic Adrenalectomy: A Comparative Study NCT02618694 | Suez Canal University | N/A |
| Completed | Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary NCT01967576 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Effect of Chronic Catecholamine Overproduction on Brown Adipose Tissue NCT01949714 | University of Aarhus | — |
| Completed | Dexmedetomidine Infusion During Laparoscopic Adrenalectomy NCT06037135 | Yonsei University | N/A |
| Completed | Phenoxybenzamine Versus Doxazosin in PCC Patients NCT01379898 | University Medical Center Groningen | Phase 4 |
| Completed | Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma NCT01425710 | Medical University of Vienna | — |
| Completed | Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease NCT00970970 | University Medical Center Groningen | — |
| Unknown | A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/ NCT00874614 | Molecular Insight Pharmaceuticals, Inc. | Phase 2 |
| Terminated | Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma NCT00911729 | Molecular Insight Pharmaceuticals, Inc. | — |
| Completed | A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanc NCT00923481 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma NCT00843037 | University Health Network, Toronto | Phase 2 |
| Completed | Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma NCT01022515 | University Hospital, Rouen | N/A |
| Completed | RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid NCT01152827 | Seoul National University Hospital | Phase 2 |
| Completed | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma NCT00458952 | Molecular Insight Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoi NCT00339131 | Molecular Insight Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblas NCT00107289 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenale NCT01959711 | Jagiellonian University | Phase 4 |
| Completed | Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers NCT00188019 | University Hospital, Angers | N/A |
| Recruiting | Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions NCT03160274 | The University of Texas Health Science Center at San Antonio | — |
| Completed | Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neurobl NCT00126412 | GE Healthcare | Phase 3 |
| Terminated | Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors NCT00466856 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Pheochromocytoma and Hemodynamic Instability NCT04566406 | Jagiellonian University | — |
| Recruiting | Adrenal Tumors - Pathogenesis and Therapy NCT00669266 | University of Wuerzburg | — |
| Completed | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors NCT00049023 | O'Dorisio, M S | Phase 1 |
| Completed | 131MIBG to Treat Malignant Pheochromocytoma NCT00028106 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 2 |
| Recruiting | Diagnosis of Pheochromocytoma NCT00004847 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1 |
| Completed | Blood Sampling for Neurochemical and Genetic Testing NCT00001147 | National Institute of Neurological Disorders and Stroke (NINDS) | — |
| Terminated | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer NCT00002947 | Yale University | Phase 1 |
| Completed | Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sa NCT00002764 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Completed | Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma NCT00002641 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Completed | Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors NCT00002608 | Ottawa Regional Cancer Centre | Phase 2 |
| Completed | A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochrom NCT01413503 | University of California, San Francisco | Phase 2 |
| Completed | I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma NCT00590096 | Children's Hospital Medical Center, Cincinnati | — |
| Completed | Diagnosis and Treatment of Pheochromocytoma NCT00001229 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| No Longer Available | 18F-FDOPA PET in Neuroendocrine Tumours NCT02431715 | British Columbia Cancer Agency | — |
| No Longer Available | Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma NCT01838187 | Children's Hospital Medical Center, Cincinnati | — |
| Available | A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastom NCT03015844 | Northwell Health | — |
| Unknown | 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors NCT01373736 | Vancouver Coastal Health | Phase 3 |
| Approved For Marketing | Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Parag NCT02961491 | Molecular Insight Pharmaceuticals, Inc. | — |
| Available | Expanded Access Protocol Using 131I-MIBG NCT01590680 | Jubilant DraxImage Inc. | — |
| Approved For Marketing | Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma NCT01377532 | University of California, San Francisco | — |